Browse the evidence

Oral administration of Lactobacillus plantarum strain Ln4 (5x10^8 CFU/day) attenuates diet-induced obesity, reduces epididymal fat mass, and improves insulin resistance in high-fat diet-fed mice.

This study suggests that consuming Lactobacillus plantarum strain Ln4 (500 million CFU daily) may help mitigate weight gain and improve insulin sensitivity in individuals consuming a high-fat diet. However, these results are from mice; human applicability is not yet established. Do not replace standard medical care with probiotics.

Astaxanthin supplementation (0.02% in diet) ameliorates insulin resistance and stimulates mitochondrial biogenesis in skeletal muscle of high-fat-diet-induced obese mice by activating the AMPK pathway.

In obese mouse models, consuming 0.02% Astaxanthin in the diet for 24 weeks improved insulin sensitivity and increased mitochondrial density in muscle by activating the AMPK pathway. This effect was independent of antioxidant activity in the muscle itself. Human translation requires caution as this was a murine model with specific dietary conditions.

Obesogens can induce transgenerational obesity through epigenetic modifications (DNA methylation, histone retention, non-coding RNA) that persist in unexposed generations.

Since environmental exposures can affect future generations, minimizing chemical exposure (plastics, pesticides) is crucial for reproductive health and the long-term metabolic health of descendants.

IL-1β antagonists (e.g., anakinra, gevokizumab) improve glycemia and beta-cell function in type 2 diabetes, but their effect on cardiovascular events is still being determined in large trials.

Blocking specific inflammatory proteins like IL-1β can improve blood sugar control and protect beta-cells in type 2 diabetes. While promising, these treatments are currently biologics (injections) and are still being studied for their long-term impact on heart disease. They represent a targeted approach to the inflammatory component of diabetes.

Salsalate, a non-acetylated salicylate, lowers blood glucose and triglycerides in type 2 diabetes by activating AMPK and inhibiting NF-κB, but its effect on cardiovascular plaque progression is unclear.

Salsalate, a form of salicylate, can lower blood sugar and triglycerides in people with type 2 diabetes by activating AMPK, a key metabolic sensor. While it shows promise for glycemic control, its effect on preventing heart disease (plaque progression) is not yet clear. It is not a standard treatment but may be considered in specific cases.

Extremely high HDL cholesterol levels (e.g., >116 mg/dL in men, >135 mg/dL in women) are associated with increased all-cause mortality.

While increasing HDL through exercise and diet is generally beneficial, aim for moderate levels. Extremely high HDL levels (above 116 mg/dL for men and 135 mg/dL for women) may not provide additional cardiovascular benefits and could be associated with higher mortality risk.

Higher expression of the cardiolipin synthase gene CRLS1 in human subcutaneous adipose tissue is positively correlated with insulin sensitivity and negatively correlated with insulin resistance.

In humans, higher levels of the enzyme that makes cardiolipin (CRLS1) in belly fat are linked to better insulin sensitivity. This suggests that supporting the health of this enzyme might be beneficial for metabolic health, although the exact way to do this is not yet defined.

Elevated circulating asprosin levels are positively associated with insulin resistance, type 2 diabetes, and obesity in adult populations, suggesting asprosin acts as a biomarker for metabolic dysregulation.

If you have insulin resistance or type 2 diabetes, your body may be producing higher levels of the hormone asprosin, which is linked to your condition. While this doesn't change your immediate treatment, it highlights the importance of managing blood sugar and weight, as lower asprosin levels are associated with better metabolic health. Future treatments may target this hormone.

Genetic mutations or activation of the Wnt/β-catenin signaling pathway, specifically involving LGR4, RSPOs, and ZNRF3/RNF43, regulate adipose tissue development and obesity risk by controlling the balance between adipocyte proliferation (hyperplasia) and differentiation (hypertrophy) in a depot-specific manner.

This research suggests that obesity is not just about calories but involves complex genetic signaling (Wnt/β-catenin) that dictates how fat cells grow and store energy. While you cannot change your genetics, understanding this helps explain why fat storage differs by body area (visceral vs. subcutaneous) and why some people are more prone to obesity. Lifestyle interventions remain relevant as they interact with these signaling pathways.

Wnt/β-catenin signaling exerts depot-specific effects on white adipose tissue (WAT), where its activation in adipose precursor cells (APs) promotes proliferation (hyperplasia) in visceral WAT (vWAT) under high-fat diet conditions, while its role in subcutaneous WAT (sWAT) involves promoting differentiation and hypertrophy of mature adipocytes.

Fat storage is not uniform across the body. The Wnt/β-catenin signaling pathway regulates how fat cells grow differently in visceral (abdominal) versus subcutaneous (under skin) areas. High-fat diets trigger this pathway to increase the number of fat cells in the visceral area, which is more metabolically harmful. This explains why visceral fat accumulation is a key risk factor for metabolic diseases.

Mutations in the LGR4 gene, specifically the A750T variant, are associated with increased obesity risk, central obesity, and metabolic complications in humans, and ablation of Lgr4 in mice resists diet-induced obesity by promoting browning of visceral white adipose tissue.

Genetic variations in the LGR4 gene can predispose individuals to central obesity and metabolic issues. In mice, removing this gene prevents obesity by promoting the browning of fat, which burns energy. This suggests that targeting the LGR4 pathway could be a potential therapeutic strategy for treating obesity and its complications.

Short-chain fatty acids (SCFAs) produced by gut microbiota influence host energy homeostasis and adipose storage through multiple mechanisms including GPCR signaling and histone deacetylase inhibition.

Increase your intake of fiber-rich foods (vegetables, fruits, whole grains) to boost SCFA production. This supports gut health and may help regulate energy balance and reduce inflammation.

Dysbiosis and increased gut permeability (leaky gut) contribute to obesity through metabolic endotoxemia and low-grade inflammation.

Focus on reducing inflammation through a balanced diet rich in anti-inflammatory foods. Addressing gut health may help manage obesity-related inflammation.

Advanced stages of MASLD (fibrosis/MASH) causally contribute to heart failure with preserved ejection fraction (HFpEF) through mechanical impediments to hepatic blood flow, reducing right ventricular preload.

If you have advanced liver fibrosis, monitor for signs of heart failure (fatigue, shortness of breath) even if your heart structure looks normal. The stiffness of your liver can mechanically impede blood flow back to the heart, contributing to HFpEF. Managing liver inflammation may help cardiac preload.

Skeletal muscle-derived myonectin confers protection against ischemia-reperfusion injury in the heart, as endurance training reduces infarct size in wild-type mice but not in myonectin-deficient mice.

Endurance training likely protects your heart against certain types of injury (like those during surgery or heart attack) through the release of myonectin. However, human blood tests for myonectin are inconsistent, so this is a protective mechanism you gain through consistent training, not something you can easily monitor or supplement.

Leptin promotes esophageal adenocarcinoma progression by acting directly on esophageal epithelial cells to increase proliferation, invasiveness, and migration, while reducing apoptosis.

There is no direct practical intervention for leptin levels in this context, but reducing visceral fat may lower circulating leptin levels, potentially reducing this specific pro-tumorigenic signaling.

Overexpression of the LAT1 transporter in vitro paradoxically decreases protein synthesis levels and BCKDHα protein content.

This finding is from a cell study, not humans, so it doesn't change your training or diet today. However, it suggests that simply having more of a specific transporter (LAT1) doesn't automatically mean your muscles will build more protein. The body has complex regulatory mechanisms that might actually suppress synthesis if certain transporters are overexpressed artificially.

The dual GLP-1/glucagon receptor agonist G49 induces rapid weight loss and metabolic rewiring in diet-induced obese mice by triggering inter-organ crosstalk, specifically white adipose tissue lipolysis, liver ketogenesis/FGF21 release, and subsequent brown adipose tissue activation.

This research suggests that combining GLP-1 and Glucagon receptor activation (like the drug G49) is more effective for weight loss and metabolic health than targeting GLP-1 alone. It works by forcing the body to burn fat (lipolysis) and activate brown fat, mimicking the effects of bariatric surgery. While promising in mice, human clinical data is not yet provided in this paper.

Ingestion of an isonitrogenous non-essential amino acid (NEAA) formulation does not stimulate muscle protein synthesis (MPS) or activate mTOR signaling pathways in skeletal muscle cells, making it an effective non-bioactive control for protein bioactivity studies.

If you are looking to stimulate muscle growth, consuming non-essential amino acids alone will not trigger the muscle-building process, even if you consume the same amount of nitrogen as protein. You need essential amino acids (found in complete proteins or EAA supplements) to activate the signaling pathways (mTOR) required for muscle protein synthesis. Use NEAA as a control or filler, not as the primary driver of muscle growth.

Use of GLP-1 receptor agonists (GLP-1 RAs) significantly reduces the risk of developing lymphedema in patients undergoing axillary lymph node dissection (ALND) for breast cancer, independent of diabetes status.

If you are having breast cancer surgery that involves removing lymph nodes, ask your doctor if GLP-1 RAs (like semaglutide or liraglutide) might help reduce your risk of lymphedema, especially if you have a higher BMI or insulin resistance. The study suggests these drugs may significantly lower the risk, but more research is needed to confirm this.

Implantation of alginate-encapsulated engineered HEKGLP-1 cells in mice, activated by endogenous or exogenous melatonin, produces GLP-1 specifically during the night phase, restoring normoglycemia in type-2 diabetic models.

This research proposes a future therapy where genetically engineered cells are implanted and protected in a capsule. These cells produce the diabetes drug GLP-1 only when melatonin levels are high (at night). Patients could take oral melatonin to control how much GLP-1 is produced, potentially allowing for once-daily dosing instead of weekly injections. This is currently only proven in mice.

Combined GIPR/GLP1R agonism significantly attenuates atherosclerosis severity (shifting lesions from severe to mild) in APOE*3-Leiden.CETP mice, an effect not achieved by single GIPR or GLP1R agonism.

This pre-clinical study suggests that combining GIP and GLP-1 receptor agonism may offer superior protection against atherosclerosis severity compared to using either hormone alone. For humans, this supports the development and use of dual-agonist therapies (like tirzepatide) for cardiovascular risk reduction, particularly in those with obesity and dyslipidemia, though clinical confirmation is required.

In obese patients without preexisting osteoarthritis, GLP-1 receptor agonist use is associated with an increased incidence of new hip and knee OA diagnoses and conversion to total knee arthroplasty within one year.

If you are obese but do not have existing hip or knee osteoarthritis, using a GLP-1 receptor agonist is associated with a higher risk of being diagnosed with new OA or needing knee replacement surgery within a year. This is unexpected given the weight loss benefits, and researchers suggest it might be due to increased physical activity stressing the joints. If you are considering these medications, discuss your joint health history with your doctor, and be aware that the benefits for joint health may primarily apply to those who already have OA.

Long-term administration of the dual GLP-1/GIP receptor agonist tirzepatide suppresses mammary tumor growth in diet-induced obese mice by reversing metabolic dysregulation and restoring CD8+ T cell function.

For individuals with obesity and hormone-sensitive or obesity-linked cancers, GLP-1/GIP agonists like tirzepatide may offer a dual benefit of weight loss and tumor suppression by correcting metabolic dysregulation. This suggests that treating obesity pharmacologically could be a viable adjunct strategy in oncology, provided lean mass is monitored.